Remove Medical Remove Mergers Remove Public Trading
article thumbnail

Private Equity’s Increasing Consolidation of Oncology Practices 

Focus Investment Banking

according to a recent report by researchers from the Harvard Medical School and the Harvard Business School that was published in JAMA Internal Medicine. Formerly owned by Tahoe Investment Group, which bought the company in April 2017, Alliance was acquired by Akumin, a publicly traded company, in June 2021 for $820 million.

article thumbnail

Cooley’s 2022 Life Sciences M&A Year in Review

Cooley M&A

But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions.

M&A 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How Private Equity uses ‘Roll-up’ Strategies to Drive Investment Returns

OfficeHours

In this industry, owning 50 to 100 or more veterinary centers gives you procurement advantages in that you can buy much higher volumes of suppliers (syringes, medical equipment, etc.) Acquisition Expertise At their core, private equity firms are mergers and acquisitions specialists.

article thumbnail

Cooley’s 2022 Tech M&A Year in Review

Cooley M&A

In the US, the Federal Trade Commission and the Department of Justice under the Biden administration have shifted their priorities and rhetoric in favor of tougher enforcement, with consolidation in the tech sector being one of their top targets. Focus on new potential theories of harm, such as the impact of mergers on labor markets.

M&A 52
article thumbnail

Cooley’s 2021 Life Sciences M&A Year in Review

Cooley M&A

For example, early in 2021, Zimmer Biomet Holdings announced that it would spin off its spine and dental businesses into a new publicly traded company as a way to “optimize resource allocation” among its remaining businesses. Biopharma favoring partnerships over M&A, with biopharma transactions in 2021 being a volume story.

M&A 40